Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05813275 · ClinicalTrials.gov registry record · Phase 3
Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)
A Phase 3 study, sponsored by Apnimed.
- Completed
- Registry status
- Phase 3
- Development phase
- 646
- Enrollment target
NCT05813275 is a Phase 3 study that has completed, run by Apnimed. The registered enrollment target is 646 participants.
The verdict
NCT05813275, a Phase 3 study, has completed, sponsored by Apnimed.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 646 participants
- Enrollment target
Study Summary
This is a Phase 3 Randomized Double-Blind Placebo-Controlled 6-month Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Obstructive Sleep Apnea.
Interventions
- DRUG Placebo
- DRUG AD109
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 646 participants |
| Start Date | 2023-09-16 |
| Est. Completion | 2025-03-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05813275
The ClinicalTrials.gov registry entry for NCT05813275 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 646 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Apnimed, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05813275 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05813275 about?
NCT05813275 is a clinical study titled "Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)". This is a Phase 3 Randomized Double-Blind Placebo-Controlled 6-month Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Obstructive Sleep Apnea.
What is the current status of trial NCT05813275?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 646 participants. The study started on 2023-09-16. Estimated completion is 2025-03-14.
What interventions are being tested in trial NCT05813275?
The interventions under investigation include: Placebo (DRUG), AD109 (DRUG).
Who is sponsoring clinical trial NCT05813275?
This trial is sponsored by Apnimed, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.